Fan Jin

Merck & Co., Inc., Rahway, NJ, USA (United States) ORCID: 0000-0002-5185-5231

2

h-index

2

Publications

5,228

Citations

Publications

2 shown

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness , Kevin J. Harrington , Richard Greil +97 more

2019 The Lancet 2928 citations

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle , Marwan Fakih , Juanita Lopez +18 more

2020 The Lancet Oncology 2300 citations

Frequent Co-Authors

Barbara Burtness

Yale Cancer Center

Kevin J. Harrington

Institute of Cancer Research

Richard Greil

Paracelsus Medical University

Denis Soulières

Centre Hospitalier de l’Université de Montréal

Makoto Tahara

National Cancer Center Hospital East

Gilberto de Castro

Instituto do Câncer do Estado de São Paulo

Researcher Info

h-index: 2
Publications: 2
Citations: 5,228
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-5185-5231

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.